These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32841336)

  • 1. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
    Roeker LE; Dreger P; Brown JR; Lahoud OB; Eyre TA; Brander DM; Skarbnik A; Coombs CC; Kim HT; Davids M; Manchini ST; George G; Shah N; Voorhees TJ; Orchard KH; Walter HS; Arumainathan AK; Sitlinger A; Park JH; Geyer MB; Zelenetz AD; Sauter CS; Giralt SA; Perales MA; Mato AR
    Blood Adv; 2020 Aug; 4(16):3977-3989. PubMed ID: 32841336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Dreger P; Michallet M; Bosman P; Dietrich S; Sobh M; Boumendil A; Nagler A; Scheid C; Cornelissen J; Niederwieser D; Müller L; Vandenberghe E; Scortechini I; Schoemans H; Andersen NS; Finke J; Russo D; Ljungman P; Passweg J; van Gelder M; Durakovic N; Labussiere-Wallet H; Berg T; Wulf G; Bethge W; Bunjes D; Stilgenbauer S; Canepari ME; Schaap M; Fox CP; Kröger N; Montoto S; Schetelig J
    Bone Marrow Transplant; 2019 Jan; 54(1):44-52. PubMed ID: 29728701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
    Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.
    Kim HT; Shaughnessy CJ; Rai SC; Reynolds C; Ho VT; Cutler C; Koreth J; Gooptu M; Romee R; Nikiforow S; Armand P; Alyea EP; Antin JH; Wu CJ; Soiffer RJ; Ritz J; Brown JR
    Blood Adv; 2020 Sep; 4(17):4113-4123. PubMed ID: 32882002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
    Helbig G; Spałek A; Wieczorkiewicz-Kabut A; Markiewicz M; Kopera M; Zielińska P; Woźniczka K; Kopińska A; Grygoruk-Wiśniowska I; Koclęga A
    Ann Hematol; 2019 Jun; 98(6):1477-1483. PubMed ID: 30919074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
    Schetelig J; Chevallier P; van Gelder M; Hoek J; Hermine O; Chakraverty R; Browne P; Milpied N; Malagola M; Socié G; Delgado J; Deconinck E; Damaj G; Maury S; Beelen D; Quoc SN; Shankara P; Brecht A; Mayer J; Hunault-Berger M; Bittenbring J; Thieblemont C; Lepretre S; Baldauf H; de Wreede LC; Tournilhac O; Yakoub-Agha I; Kröger N; Dreger P
    Bone Marrow Transplant; 2021 Mar; 56(3):605-613. PubMed ID: 33004942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
    Hsu J; Artz A; Mayer SA; Guarner D; Bishop MR; Reich-Slotky R; Smith SM; Greenberg J; Kline J; Ferrante R; Phillips AA; Gergis U; Liu H; Stock W; Cushing M; Shore TB; van Besien K
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):359-365. PubMed ID: 29128555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
    Hahn M; Böttcher S; Dietrich S; Hegenbart U; Rieger M; Stadtherr P; Bondong A; Schulz R; Ritgen M; Schmitt T; Tran TH; Görner M; Herth I; Luft T; Schönland S; Witzens-Harig M; Zenz T; Kneba M; Ho AD; Dreger P
    Bone Marrow Transplant; 2015 Oct; 50(10):1279-85. PubMed ID: 26146810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
    van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group.
    Gołos A; Gil L; Puła B; Boguradzki P; Hałaburda K; Sawicki W; Sobczyk-Kruszelnicka M; Helbig G; Dybko J; Jurczyszyn A; Dębek S; Warzocha K; Jamroziak K
    Adv Med Sci; 2020 Sep; 65(2):429-436. PubMed ID: 32919120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
    Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.
    Lahoud OB; Devlin SM; Maloy MA; Roeker LE; Dahi PB; Ponce DM; Gyurkocza B; Koehne G; Young JW; Castro-Malaspina HR; Barker JN; Papadopoulos EB; Jakubowski AA; Zelenetz AD; Mato AR; Giralt SA; Perales MA; Sauter CS
    Blood Adv; 2021 Jul; 5(14):2879-2889. PubMed ID: 34297048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Aldoss I; Tsai NC; Slovak ML; Palmer J; Alvarnas J; Marcucci G; Forman SJ; Pullarkat V
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1212-1217. PubMed ID: 27044907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them.
    Chhabra S; Szabo A; Glisch C; George G; Narra RK; Harrington A; Jerkins JH; D'Souza A; Dhakal B; Pasquini MC; Hamadani M; Hari PN
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1288-1297. PubMed ID: 32135202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia.
    Jindra P; Raida L; Lysak D; Karas M; Papajik T; Jungova A; Mohammadová L; Houdova L
    Neoplasma; 2016; 63(4):595-600. PubMed ID: 27268923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults.
    Sugidono M; Lo M; Young R; Rosario K; Jung Y; Huang CY; Sheng Y; Huang LW; Olin RL
    Transplant Cell Ther; 2021 Apr; 27(4):344.e1-344.e5. PubMed ID: 33836888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.